Nectar Lifesciences
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
March 2 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD - TO ACQUIRE 100% PAID- UP EQUITY SHARE CAPITAL OF AVENSIS EXPORTS
NECTAR LIFESCIENCES LTD - ACQUISITION COST FOR AVENSIS EXPORTS SET AT 2.5 MILLION RUPEES
Source text: ID:nNSE85X3Jz
Further company coverage: NECT.NS
(([email protected];))
March 2 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD - TO ACQUIRE 100% PAID- UP EQUITY SHARE CAPITAL OF AVENSIS EXPORTS
NECTAR LIFESCIENCES LTD - ACQUISITION COST FOR AVENSIS EXPORTS SET AT 2.5 MILLION RUPEES
Source text: ID:nNSE85X3Jz
Further company coverage: NECT.NS
(([email protected];))
** Shares of Nectar Lifesciences NECT.NS jump 15.2% to 16.31 rupees
** Pharmaceuticals co's board to meet on December 3 to consider buyback of shares
** NECT down ~58% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Nectar Lifesciences NECT.NS jump 15.2% to 16.31 rupees
** Pharmaceuticals co's board to meet on December 3 to consider buyback of shares
** NECT down ~58% YTD
(Reporting by Vijay Malkar)
(([email protected];))
Sept 16 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES- DIRECTORATE OF REVENUE INTELLIGENCE CONDUCTED SEARCH OPERATIONS AT PREMISES OF CO
NECTAR LIFESCIENCES- CO RESPONDED TO CLARIFICATIONS AND DETAILS SOUGHT BY AUTHORITY
Source text: [ID:]
Further company coverage: NECT.NS
(([email protected];))
Sept 16 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES- DIRECTORATE OF REVENUE INTELLIGENCE CONDUCTED SEARCH OPERATIONS AT PREMISES OF CO
NECTAR LIFESCIENCES- CO RESPONDED TO CLARIFICATIONS AND DETAILS SOUGHT BY AUTHORITY
Source text: [ID:]
Further company coverage: NECT.NS
(([email protected];))
July 8 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD - SELLS API BUSINESS FOR 12.70 BILLION RUPEES
NECTAR LIFESCIENCES LTD - SELLS MENTHOL ASSETS FOR 200 MILLION RUPEES
Source text: ID:nBSE11LB3p
Further company coverage: NECT.NS
(([email protected];))
July 8 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD - SELLS API BUSINESS FOR 12.70 BILLION RUPEES
NECTAR LIFESCIENCES LTD - SELLS MENTHOL ASSETS FOR 200 MILLION RUPEES
Source text: ID:nBSE11LB3p
Further company coverage: NECT.NS
(([email protected];))
April 30 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
UNIT II AT SAIDPURA RECEIVES GMP CERTIFICATION FROM ANVISA BRAZIL
CERTIFICATION VALID FOR TWO YEARS FROM APRIL 28, 2025
Source text: ID:nNSE82Q9DG
Further company coverage: NECT.NS
(([email protected];;))
April 30 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
UNIT II AT SAIDPURA RECEIVES GMP CERTIFICATION FROM ANVISA BRAZIL
CERTIFICATION VALID FOR TWO YEARS FROM APRIL 28, 2025
Source text: ID:nNSE82Q9DG
Further company coverage: NECT.NS
(([email protected];;))
** Nectar Lifesciences NECT.NS drops exchange-allowed maximum of 5% to 26.37 rupees
** European Directorate for Quality of Medicines & HealthCare and Spanish Agency of Medicines and Medical Devices issue seven observations to co's API manufacturing facility in Punjab's Mohali
** Co says it will prepare corrective action and preventive action report to address observations
** NECT falls 32.4% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Nectar Lifesciences NECT.NS drops exchange-allowed maximum of 5% to 26.37 rupees
** European Directorate for Quality of Medicines & HealthCare and Spanish Agency of Medicines and Medical Devices issue seven observations to co's API manufacturing facility in Punjab's Mohali
** Co says it will prepare corrective action and preventive action report to address observations
** NECT falls 32.4% YTD
(Reporting by Vijay Malkar)
(([email protected];))
March 10 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
API MANUFACTURING FACILITY, PUNJAB UNDERGONE JOINT INSPECTION BY EDQM, AEMPS
FOLLOWING INSPECTION, SEVEN OBSERVATIONS INCLUDING FOUR CRITICAL, WERE NOTED.
EUROPEAN REGULATOR WILL CONDUCT A RE-INSPECTION OF FACILITY
Further company coverage: NECT.NS
(([email protected];;))
March 10 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
API MANUFACTURING FACILITY, PUNJAB UNDERGONE JOINT INSPECTION BY EDQM, AEMPS
FOLLOWING INSPECTION, SEVEN OBSERVATIONS INCLUDING FOUR CRITICAL, WERE NOTED.
EUROPEAN REGULATOR WILL CONDUCT A RE-INSPECTION OF FACILITY
Further company coverage: NECT.NS
(([email protected];;))
Jan 20 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
RECEIVES TAX RELIEF OF 35.8 MILLION RUPEES
Source text: ID:nBSEbbd3nF
Further company coverage: NECT.NS
(([email protected];;))
Jan 20 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
RECEIVES TAX RELIEF OF 35.8 MILLION RUPEES
Source text: ID:nBSEbbd3nF
Further company coverage: NECT.NS
(([email protected];;))
Dec 13 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
ISENGARD DIRECT PE LLC, ITS ASSOCIATES HAVE SOLD ALL OF THEIR SHARES
INVESTMENT AGREEMENT WITH ISENGARD DIRECT PE LLC STANDS TERMINATED
Source text: ID:nNSE6xx3JW
Further company coverage: NECT.NS
(([email protected];;))
Dec 13 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
ISENGARD DIRECT PE LLC, ITS ASSOCIATES HAVE SOLD ALL OF THEIR SHARES
INVESTMENT AGREEMENT WITH ISENGARD DIRECT PE LLC STANDS TERMINATED
Source text: ID:nNSE6xx3JW
Further company coverage: NECT.NS
(([email protected];;))
Nov 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 56 MILLION RUPEES
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.28 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
Nov 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 56 MILLION RUPEES
NECTAR LIFESCIENCES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.28 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 29.7 MILLION RUPEES
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.59 BILLION RUPEES
Source text for Eikon: ID:nBSEc02H56
Further company coverage: NECT.NS
(([email protected];))
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 29.7 MILLION RUPEES
NECTAR LIFESCIENCES LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.59 BILLION RUPEES
Source text for Eikon: ID:nBSEc02H56
Further company coverage: NECT.NS
(([email protected];))
May 15 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.9 MILLION RUPEES VERSUS PROFIT 36.8 MILLION RUPEES
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 3.88 BILLION RUPEES
Source text for Eikon: ID:nBSE392nGx
Further company coverage: NECT.NS
(([email protected];;))
May 15 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 5.9 MILLION RUPEES VERSUS PROFIT 36.8 MILLION RUPEES
NECTAR LIFESCIENCES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 3.88 BILLION RUPEES
Source text for Eikon: ID:nBSE392nGx
Further company coverage: NECT.NS
(([email protected];;))
Feb 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES DEC-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 15.7 MILLION RUPEES VERSUS LOSS 92.9 MILLION RUPEES
NECTAR LIFESCIENCES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.52 BILLION RUPEES VERSUS 3.44 BILLION RUPEES
Source text for Eikon: ID:nBSE6MsHdt
Further company coverage: NECT.NS
(([email protected];;))
Feb 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
NECTAR LIFESCIENCES DEC-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 15.7 MILLION RUPEES VERSUS LOSS 92.9 MILLION RUPEES
NECTAR LIFESCIENCES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.52 BILLION RUPEES VERSUS 3.44 BILLION RUPEES
Source text for Eikon: ID:nBSE6MsHdt
Further company coverage: NECT.NS
(([email protected];;))
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
INDIA'S NECTAR LIFESCIENCES JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 18.2 MILLION RUPEES VERSUS PROFIT 39 MILLION RUPEES
NECTAR LIFESCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.94 BILLION RUPEES VERSUS 4.03 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
Aug 14 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
INDIA'S NECTAR LIFESCIENCES JUNE-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 18.2 MILLION RUPEES VERSUS PROFIT 39 MILLION RUPEES
NECTAR LIFESCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.94 BILLION RUPEES VERSUS 4.03 BILLION RUPEES
Further company coverage: NECT.NS
(([email protected];))
May 26 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 36.8 MILLION RUPEES VERSUS 116.6 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.88 BILLION RUPEES VERSUS 4.76 BILLION RUPEES
Source text for Eikon: ID:nBSE1Vq5DQ
Further company coverage: NECT.NS
(([email protected];))
May 26 (Reuters) - Nectar Lifesciences Ltd NECT.NS:
MARCH-QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 36.8 MILLION RUPEES VERSUS 116.6 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.88 BILLION RUPEES VERSUS 4.76 BILLION RUPEES
Source text for Eikon: ID:nBSE1Vq5DQ
Further company coverage: NECT.NS
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Nectar Lifesciences do?
Nectar Lifesciences is a key player in the Indian Pharmaceutical Industry, specializing in Global Cephalosporins within Anti Infective Therapeutic segment. The company is expanding globally by entering regulated markets like US and European Union.
Who are the competitors of Nectar Lifesciences?
Nectar Lifesciences major competitors are Everest Organics, Bal Pharma, Smruthi Organics, Tyche Inds, Mangalam Drugs&Org., Lasa Supergenerics, Haleos Labs. Market Cap of Nectar Lifesciences is ₹223 Crs. While the median market cap of its peers are ₹135 Crs.
Is Nectar Lifesciences financially stable compared to its competitors?
Nectar Lifesciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Nectar Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Nectar Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Nectar Lifesciences allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances
How strong is Nectar Lifesciences balance sheet?
Balance sheet of Nectar Lifesciences is strong. But short term working capital might become an issue for this company.
Is the profitablity of Nectar Lifesciences improving?
No, profit is decreasing. The profit of Nectar Lifesciences is -₹292.89 Crs for TTM, -₹113.68 Crs for Mar 2025 and ₹5 Crs for Mar 2024.
Is the debt of Nectar Lifesciences increasing or decreasing?
The net debt of Nectar Lifesciences is decreasing. Latest net debt of Nectar Lifesciences is -₹112.13 Crs as of Mar-26. This is less than Mar-25 when it was ₹546 Crs.
Is Nectar Lifesciences stock expensive?
Nectar Lifesciences is not expensive. Latest PE of Nectar Lifesciences is 0, while 3 year average PE is 45.37. Also latest EV/EBITDA of Nectar Lifesciences is 0.0 while 3yr average is 9.9.
Has the share price of Nectar Lifesciences grown faster than its competition?
Nectar Lifesciences has given lower returns compared to its competitors. Nectar Lifesciences has grown at ~-9.36% over the last 8yrs while peers have grown at a median rate of 6.51%
Is the promoter bullish about Nectar Lifesciences?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 51.84% and last quarter promoter holding is 44.91%.
Are mutual funds buying/selling Nectar Lifesciences?
There is Insufficient data to gauge this.